A growing body of literature has revealed that patients with endometriosis are at an increased risk for epithelial ovarian cancer (EOC) and cardiovascular disease (CVD). Endometriosis is a heterogeneous disease …
To evaluate the effects of a combined programme of therapeutic exercise (TE) and pain neurophysiology education (PNE) on health-related quality of life (HRQoL), abdominal wall muscle thickness, menstrual symptoms and …
Bowel involvement is a severe manifestation of deep endometriosis that affects approximately 8-12% of women with endometriosis. Bowel endometriosis is most commonly localised in the rectosigmoid colon and frequently coexists …
Background/Objectives: Gastrointestinal (GI) symptoms, including abdominal pain, bloating, altered stool pattern, dyschezia, and nausea, are frequent in women with endometriosis and may persist despite conventional gynecological treatment. The low fermentable …
Endometriosis symptoms often first appear during adolescence, yet delays in seeking gynecologic consultation remain a persistent challenge worldwide. Despite growing international evidence, the specific patterns of symptom recognition and consultation …
Are there distinct symptom clusters in women with endometriosis and adenomyosis, and how do these clusters predict quality of life?
Endometriosis is a chronic inflammatory disorder that affects 5-15% of women of reproductive age. It is characterized by severe symptoms, including dysmenorrhea and non-cyclic pelvic pain, which can substantially impair …
Microvascular thromboinflammation is a pervasive yet under-recognized driver of multisystem morbidity that links focal endothelial injury to distal organ dysfunction through interacting cellular and plasmatic networks. Contemporary paradigms remain fragmented: …
Buserelin, a gonadotropin-releasing hormone agonist, reduces gonadotropin and estrogen levels and is commonly used to alleviate the symptoms of endometriosis. Vitamin D3 has been reported to exhibit anti-inflammatory and pro-apoptotic …
To investigate the association between Central Sensitization Inventory (CSI) scores/Central Sensitization (CS) and hormonal therapy failure (HTF) for endometriosis.